- Home
- UPWK vs XERS Comparison
UPWK vs XERS Comparison
Compare UPWK & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPWK | XERS |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | 630 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UPWK | XERS |
|---|---|---|
| Price | $8.78 | $6.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $22.73 | $10.83 |
| AVG Volume (30 Days) | ★ 4.8M | 1.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 0.24 | 0.01 |
| Revenue | ★ $787,784,000.00 | $49,590,000.00 |
| Revenue This Year | $9.06 | $34.37 |
| Revenue Next Year | $13.57 | $22.86 |
| P/E Ratio | ★ $36.42 | $615.00 |
| Revenue Growth | 2.40 | ★ 142.67 |
| 52 Week Low | $7.44 | $4.30 |
| 52 Week High | $22.84 | $10.08 |
Technical Indicators
Market Signals| Indicator | UPWK | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 50.56 |
| Support Level | $7.44 | $5.81 |
| Resistance Level | $11.79 | $6.42 |
| Average True Range (ATR) | 0.41 | 0.24 |
| MACD | 0.11 | -0.02 |
| Stochastic Oscillator | 51.56 | 58.40 |
Price Performance
Historical ComparisonAbout UPWK Upwork Inc.
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes and connects businesses with AI-enabled talent across every on-demand work type, including freelance, agency, fractional, and payrolled. The business generates revenue from Talent and Clients across the USA, India, Pakistan, the Philippines and the rest of the world. Maximum revenue of the company is derived from Talent segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.